Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 483
Clinics ; 76: e2348, 2021. graf
Article in English | LILACS | ID: biblio-1153978


OBJECTIVES: TTP488, an antagonist of the receptor for advanced glycation end-products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD). However, the mechanism underlying the protective action of TTP488 against AD has not yet been fully explored. METHODS: Healthy male rats were exposed to aberrant amyloid β (Aβ) 1-42. Lipopolysaccharide (LPS) and the NOD-like receptor family pyrin domain containing 1 (NLRP1) overexpression lentivirus were injected to activate the NLRP1 inflammasome and exacerbate AD. TTP488 was administered to reverse AD injury. Finally, tofacitinib and fludarabine were used to inhibit the activity of Janus tyrosine kinase (JAK) and signal transducer and activator of transcription (STAT) to prove the relationship between the JAK/STAT signaling pathway and TTP488. RESULTS: LPS and NLRP1 overexpression significantly increased the NLRP1 levels, reduced neurological function, and aggravated neuronal damage, as demonstrated by the impact latency time of, time spent by, and length of the platform covered by, the mice in the Morris water maze assay, Nissl staining, and immunofluorescence staining in rats with AD. CONCLUSIONS: TTP488 administration successfully reduced AD injury and reversed the aforementioned processes. Additionally, tofacitinib and fludarabine administration could further reverse AD injury after the TTP488 intervention. These results suggest a new potential mechanism underlying the TTP488-mediated alleviation of AD injury.

Animals , Male , Mice , Rats , Janus Kinases/metabolism , Alzheimer Disease/drug therapy , Tyrosine , Transducers , Signal Transduction , Amyloid beta-Peptides , Janus Kinase 2 , Receptor for Advanced Glycation End Products , Imidazoles
Chinese Journal of Biotechnology ; (12): 3348-3360, 2021.
Article in Chinese | WPRIM | ID: wpr-921430


Tyrosine is an important aromatic amino acid. Besides its nutritional value, tyrosine is also an important precursor for the synthesis of coumarins and flavonoids. Previously, our laboratory constructed a Saccharomyces cerevisiae strain LTH0 (ARO4K229L, ARO7G141S, Δaro10, Δzwf1, Δura3) where tyrosine feedback inhibition was released. In the present study, heterologous expression of betaxanthins synthesis genes DOD (from Mirabilis jalapa) and CYP76AD1 (from sugar beet B. vulgaris) in strain LTH0 enabled production of yellow fluorescence. The engineered strain LTH0-DOD-CYP76AD1 was subjected to UV combined with ARTP mutagenesis, followed by flow cytometry screening. Among the mutants screened, the fluorescence intensity of the mutant strain LTH2-5-DOD-CYP76AD1 at the excitation wavelength of 485 nm and emission wavelength of 505 nm was (5 941±435) AU/OD, which was 8.37 times higher than that of strain LTH0-DOD-CYP76AD1. Fourteen mutant strains were subjected to fermentation to evaluate their tyrosine producing ability. The highest extracellular tyrosine titer reached 26.8 mg/L, which was 3.96 times higher than that of strain LTH0-DOD-CYP76AD1. Heterologous expression of the tyrosine ammonia lyase FjTAL derived from Flavobacterium johnsoniae further increased the titer of coumaric acid to 119.8 mg/L, which was 1.02 times higher than that of the original strain LTH0-FjTAL.

Flavobacterium , High-Throughput Screening Assays , Mirabilis , Saccharomyces cerevisiae/genetics , Tyrosine
Chinese Journal of Biotechnology ; (12): 100-111, 2021.
Article in Chinese | WPRIM | ID: wpr-878546


The enrichment of tyrosine phosphorylation sites plays an important role in the study of tyrosine phosphoproteomics and the commonly used enrichment methods are antibody affinity enrichment and SH2 superbinder enrichment. In addition, in order to achieve large-scale identification of tyrosine phosphorylation sites, biological mass spectrometry and bioinformatics have been applied in tyrosine phosphoproteomics. In-depth coverage research of tyrosine phosphoproteomics, revealing the dysregulated kinases in cancer process, may help us understanding the occurrence and development process of cancer. According to literature reports, three quarters of the oncogenes are tyrosine kinase genes. Therefore, tyrosine kinase inhibitors have received more and more attention as anticancer drugs. The application of tyrosine phosphoproteomics technology can identify tyrosine kinases related to cancer and other major diseases, so as to help finding tyrosine kinase inhibitors. In short, tyrosine phosphoproteomics technology can be applied in biomedical fields such as tyrosine kinase identification, tyrosine kinase inhibitor research, and tyrosine phosphorylation signal pathway research.

Biomedical Research , Mass Spectrometry , Phosphorylation , Proteomics , Tyrosine/metabolism
Chinese Journal of Biotechnology ; (12): 2334-2341, 2021.
Article in Chinese | WPRIM | ID: wpr-887800


Tyrosine phosphorylation is one of the important protein phosphorylations in eukaryotes responsible for a variety of biological processes including cell signaling transduction, cell migration, and apoptosis. In the study of phosphoproteomics, due to the low stoichiometry of tyrosine phosphorylation (pTyr) proteins and sometimes limited initial sample, traditional phosphoproteomics enrichment technology is inefficient for the enrichment of pTyr peptides. Here, we review the substantial progress in tyrosine phosphoproteomics by preparation of limited amount sample and the newly introduced SH2 superbinder.

Cell Movement , Peptides , Phosphorylation , Technology , Tyrosine/metabolism
Int. j. morphol ; 38(4): 919-923, Aug. 2020. tab, graf
Article in English | LILACS | ID: biblio-1124877


Letrozole (Letro) is a drug commonly used for breast cancer treatment since it can decrease estrogen level. In experimental animal, the Letro has been used to induce the polycystic ovarian syndrome (PCOS) model. Tyrosine phosphorylation (TyrPho) is an essential process in various biological functions both normal and abnormal conditions especially reproduction. Although some side effects of Letro are reported, the alterations of TyrPho responsible for liver and kidney functions have never been demonstrated. In this study, the blood serum, liver, and kidney of control and PCOS rats induced with Letro (orally, 1 mg/ KgBW) for consecutive 21 days were used to determine the serum biochemical components and to investigate the TyrPho expression using western blot analysis. Histopathology of such tissues was observed by Masson's trichrome staining. The results showed that Letro did not affect histological structures but significantly increased the serum levels of urea nitrogen, cholesterol, triglyceride, HDL, LDL, ALT, AST, and alkaline phosphatase. Additionally, the TyrPho protein expressions of 32 and 27 kDas in liver and of 55 and 43 kDas in kidney were increased while of a kidney 26 kDa was decreased as compared to those of control. In conclusion, this recent study indicated that the changes of TyrPho proteins in liver and kidney induced with Letro associated with their functions by alteration of serum biochemical levels.

El letrozol (Letro) es un medicamento utilizado comúnmente para el tratamiento del cáncer de mama, debido a que puede disminuir el nivel de estrógeno. En animales de experimentación, el Letro se ha utilizado para inducir el modelo de síndrome de ovario poliquístico (PCOS). La fosforilación de tirosina (TyrPho) es un proceso esencial en diversas funciones biológicas, tanto en condiciones normales como anormales, especialmente en la reproducción. A pesar de informes que indican algunos efectos secundarios de Letro, no se han demostrado las alteraciones de TyrPho responsables de las funciones hepáticas y renales. En este estudio, el suero sanguíneo, el hígado y el riñón control y las ratas PCOS inducidas con Letro (por vía oral, 1 mg / KgBW) durante 21 días consecutivos se usaron para determinar los componentes bioquímicos del suero y para investigar la expresión de TyrPho usando análisis de transferencia Western. La histopatología de los tejidos se observó mediante la tinción tricrómica de Masson. Los resultados mostraron que Letro no afectó las estructuras histológicas, pero aumentó significativamente los niveles séricos de urea, colesterol, triglicéridos, HDL, LDL, ALT, AST y fosfatasa alcalina. Además, las expresiones de la proteína TyrPho de 32 y 27 kDas en el hígado y de 55 y 43 kDas en el riñón aumentaron mientras que en un riñón disminuyeron 26 kDa en comparación con el control. En conclusión, este estudio indicó que los cambios de las proteínas TyrPho en el hígado y los riñones inducidos con Letro se asociaron con sus funciones mediante la alteración de los niveles bioquímicos en suero.

Animals , Female , Rats , Polycystic Ovary Syndrome/chemically induced , Letrozole/adverse effects , Kidney/drug effects , Liver/drug effects , Phosphorylation/physiology , Tyrosine/metabolism , Blotting, Western , Rats, Wistar , Disease Models, Animal , Electrophoresis, Polyacrylamide Gel
Acta bioquím. clín. latinoam ; 54(2): 125-133, jun. 2020. graf, tab
Article in Spanish | LILACS | ID: biblio-1130587


El objetivo del trabajo fue evaluar la utilidad clínica de la relación factor de crecimiento placentario/receptor de tirosin-quinasa tipo 1 soluble (sFlt-1/ PlGF) para el diagnóstico de preeclampsia (PE) en embarazadas de alto riesgo y con diagnóstico clínico de PE en un centro de salud de Córdoba, Argentina. Se procesaron 135 muestras de embarazadas: 39 con diagnóstico clínico de PE (Grupo I), 72 con riesgo de PE (Grupo II), y 24 de grupo control (Grupo III). Se utilizó una técnica automatizada de electroquimioluminiscencia (Roche). Valores <38 se consideraron sin riesgo de PE, entre 38 y 85 (< semana 34) o 38 y 110 (> semana 34) con riesgo moderado o alto riesgo dentro de las 4 semanas posteriores a la realización de dichos marcadores y >85 en embarazadas con síntomas de aparición temprana o >110 en embarazadas con síntomas de aparición tardía, PE confirmada. En el Grupo I, 33 muestras dieron relación >38 y 6 fueron menores. De 72 muestras del Grupo II 69 dieron <38 y 3 >38. Todas las muestras del Grupo III dieron relación <38. La razón de verosimilitud positiva (LR+) fue de 20,31 y la razón negativa (LR-) fue de 0,16. La relación fue >38 en la mayoría de las embarazadas con diagnóstico de PE. La determinación es útil en aquellas mujeres embarazadas que son de alto riesgo, ya sea porque tienen hipertensión o proteinuria o algún antecedente previo, en las cuales puede ser fundamental para decidir el correcto diagnóstico.

The objective of this work was to evaluate the clinical usefulness of the relation placental growth factor/soluble tyrosine-kinase type 1 receptor (sFlt-1/PlGF) for the diagnosis of PE (preeclampsia) in pregnant women at high risk and with clinical diagnosis of PE in a health center of Córdoba, Argentina. A total of 135 samples of pregnant women were processed: 39 with clinical diagnosis of PE (Group I), 72 with risk of PE (Group II), and 24 of control group (Group III). An automated electrochemiluminescence technique (Roche) was used. Ratio sFlt-1/PlGF <38 was considered without risk of PE. Between 38 and 85 (< week 34) or 38 and 110 (> week 34), with moderate risk or high risk within 4 weeks after performing these markers. To confirm diagnosis, relationships >85 in pregnant women were considered with symptoms of early onset and >110 in pregnant women with symptoms of late onset. In Group I, 33 samples reported >38 and 6 were lower. Of 72 samples from Group II, 69 gave <38 and 3, >38. All samples from Group III gave a ratio <38. The positive likelihood ratio (LR+) was 20.31 and the negative likelihood ratio (LR-), 0.16. The ratio was >38 in the majority of women already diagnosed as PE. The test is useful in those pregnant women who are at high risk of PE, either because they have hypertension or proteinuria or a previous history. In those cases it can be fundamental to decide the correct diagnosis.

O objetivo do estudo é avaliar a utilidade clínica da relação fator de crescimento placentário/receptor de tirosina-quinase tipo 1 solúvel (sFlt-1/PIGF) para o diagnóstico de pré-eclâmpsia (PE) em grávidas de alto risco e com diagnóstico clínico de PE em um centro de saúde de Córdoba, Argentina. Foram processadas 135 amostras de gestantes, sendo 39 com diagnóstico clínico de PE (Grupo I), 72 com risco de PE (Grupo II) e 24 de grupo controle (Grupo III). Foi utilizada uma técnica automatizada de eletroquimioluminescência (Roche). Valores <38 foram considerados sem risco de PE, entre 38 e 85 (

Humans , Female , Pregnancy , Pre-Eclampsia , Tyrosine , Placenta Growth Factor , Hypertension , Signs and Symptoms , Health Centers , Risk , Control Groups , Determination , Pregnant Women , Diagnosis , Control , Growth
Article in English | WPRIM | ID: wpr-812987


Protein tyrosine phosphatase H-type receptor (PTPRH) gene encodes a gastric cancer associated protein, which exerts its biological function through tyrosine phosphorylation in the post-translational COOH- terminal region. PTPRH is abnormally expressed in a variety of tumors, and its biological function is closely related to the occurrence, development and prognosis of tumors.

Humans , Phosphorylation , Protein Tyrosine Phosphatases , Proteins , Stomach Neoplasms , Tyrosine
Chinese Journal of Biotechnology ; (12): 2367-2376, 2020.
Article in Chinese | WPRIM | ID: wpr-878493


p-coumaric acid is an important natural phenolic compound with a variety of pharmacological activities, and also a precursor for the biosynthesis of many natural compounds. It is widely used in foods, cosmetics and medicines. Compared with the chemical synthesis and plant extraction, microbial production of p-coumaric acid has many advantages, such as energy saving and emission reduction. However, the yield of p-coumaric acid by microbial synthesis is too low to meet the requirements of large-scale industrial production. Here, to further improve p-coumaric acid production, the directed evolution of tyrosine ammonia lyase (TAL) encoded by Rhodotorula glutinis tal gene was conducted, and a high-throughput screening method was established to screen the mutant library for improve the property of TAL. A mutant with a doubled TAL catalytic activity was screened from about 10,000 colonies of the mutant library. There were three mutational amino acid sites in this TAL, namely S9Y, A11N, and E518A. It was further verified by a single point saturation mutation. When S9 was mutated to Y, I or N, or A11 was mutated to N, T or Y, the catalytic activity of TAL increased by more than 1-fold. Through combinatorial mutation of three types of mutations at the S9 and A11, the TAL catalytic activity of S9Y/A11N or S9N/A11Y mutants were significantly higher than that of other mutants. Then, the plasmid containing S9N/A11Y mutant was transformed into CP032, a tyrosine-producing E. coli strain. The engineered strain produced 394.2 mg/L p-coumaric acid, which is 2.2-fold higher than that of the control strain, via shake flask fermentation at 48 h. This work provides a new insight for the biosynthesis study of p-coumaric acid.

Ammonia-Lyases/genetics , Escherichia coli/genetics , Propionates , Rhodotorula , Tyrosine/genetics
Int. j. morphol ; 37(4): 1463-1468, Dec. 2019. graf
Article in English | LILACS | ID: biblio-1040154


Acute effect of purified mimosine (MiMo) extracted from Leucaena leucocephala on testicular histopathology has been documented with seminal vesicle (SV) atrophy. Since protein phosphorylation and seminal secretions play important roles in sperm physiology, this study aimed to study the alteration of substances including tyrosine phosphorylated (TyrPho) proteins in seminal vesicle treated with MiMo. Male mice were divided into a control and experimental groups treated with purified MiMo at 3 doses of 15, 30, and 60 mg/KgBW, respectively for 35 consecutive days. The morphology and weights of SV were compared among groups. The levels of magnesium and fructosamine in SV fluid were assayed. The profiles of equally SV total proteins were compared using SDS-PAGE. The expression of seminal TyrPho proteins was detected by western blotting. Recent results showed the decreased weights of SV in MiMo treated mice compared to control. However MiMo in all doses did not affect the levels of magnesium and fructosamine in SV fluid. The SV protein expression of 130 and 55 kDas was obviously decreased in a high dose MiMo. In dose-dependent response, the expressions of 72 and 55 kDas TyrPho proteins of SV were increased. In conclusion, MiMo could affect SV morphological size and protein secretions especially TyrPho proteins.

El efecto agudo de la mimosina purificada (MiMo) extraída de Leucaena leucocephala en la histopatología testicular se ha documentado con atrofia de vesícula seminal (VS). Debido a que la fosforilación de proteínas y las secreciones seminales tienen un papel importante en la fisiología de los espermatozoides, este estudio tuvo como objetivo estudiar la alteración de sustancias como la proteína tirosina fosforilada (TyrPho) en vesículas seminales tratadas con MiMo. Los ratones se dividieron en un grupo control y un grupo experimental y se trataron con MiMo purificado en 3 dosis de 15, 30 y 60 mg / KgBW, respectivamente, durante 35 días seguidos. La morfología y los pesos de VS se compararon entre los grupos. Fueron analizados los niveles de magnesio y fructosamina en el fluido VS. Los perfiles de las proteínas totales de VS se compararon utilizando SDS-PAGE. La expresión de la proteína TyrPho en las vesículas seminales se detectó mediante transferencia de Western blot. Los resultados recientes muestran la disminución del peso de las VS en ratones tratados con MiMo, en comparación con el grupo control. Sin embargo, en ninguna de las dosis se vieron afectados por mimosina purificada los niveles de magnesio y fructosamina en el líquido de las VS. La expresión de la proteína en VS de 130 y 55 kDas disminuyó notablemente en una dosis alta de MiMo. En la respuesta dependiente de la dosis, aumentaron las expresiones de 72 y 55 kDas de las proteínas TyrPho en las VS. En conclusión, la mimosina purificada podría afectar el tamaño morfológico de las VS y la expresión de proteínas, especialmente las proteínas TyrPho.

Animals , Male , Mice , Phosphoproteins/drug effects , Seminal Vesicles/drug effects , Mimosine/administration & dosage , Organ Size , Phosphoproteins/metabolism , Phosphorylation , Seminal Vesicles/pathology , Tyrosine/analogs & derivatives , Blotting, Western , Phosphotyrosine , Electrophoresis, Polyacrylamide Gel , Mice, Inbred ICR , Mimosine/pharmacology
Medicina (B.Aires) ; 79(supl.3): 2-5, set. 2019. tab
Article in Spanish | LILACS | ID: biblio-1040540


La fenilcetonuria, también conocida como PKU, es el error congénito más frecuente del metabolismo de los aminoácidos. La forma grave o PKU clásica no tratada, causa una discapacidad intelectual, aunque los programas de detección en el período neonatal, el diagnóstico y el tratamiento evitan la aparición de los síntomas. A pesar de un diagnóstico y tratamiento temprano hemos observado cierta neurotoxicidad en los pacientes con PKU tratados. Analizamos los demás factores implicados, aparte de la toxicidad por las elevadas concentraciones cerebrales de fenilalanina (Phe), se revisan los defectos de síntesis de neurotransmisores, las alteración de la mielinización cerebral, el efecto de la elevación de Phe en los procesos de transporte y distribución de los aminoácidos neutros con una síntesis anómala de proteínas cerebrales, la deficiencia plasmática y cerebral de tirosina, la neurotoxicidad de los metabolitos de Phe, el defecto de la biosíntesis del colesterol o el aumento del estrés oxidativo. Las alteraciones de la sustancia blanca en los pacientes con PKU tienen un papel importante en las manifestaciones neurológicas. El tratamiento de la PKU es para toda la vida y se basa en la reducción del aporte de alimentos que contienen Phe combinado con la administración de una fórmula especial, o en el tratamiento con tetrahidrobiopterina (BH4). Se analizan nuevas opciones terapéuticas.

Phenylketonuria, also known as PKU, is the most frequent congenital inborn error of metabolism. The severe form or classic PKU untreated causes intellectual disability, although with the early detection programs in the neonatal period, diagnosis and treatment prevent the appearance of the symptoms. Despite early diagnosis and treatment we have observed some neurotoxicity in treated PKU patients. We analyzed the factors involved apart from the toxicity due to the high cerebral concentrations of phenylalanine (Phe), the defects of synthesis of neurotransmitters, the alteration of cerebral myelination, the effect of the elevation of Phe in the processes of transport and distribution of neutral amino acids with an abnormal synthesis of brain proteins, plasma and cerebral tyrosine deficiency, the neurotoxicity of Phe metabolites, the defect of cholesterol biosynthesis or the increase of oxidative stress. White matter alterations in early treated PKU patients have an important role in neurological manifestations. The treatment of PKU is for life and is based on the reduction of foods containing Phe combined with the administration of a special formula or tetrahydrobiopterin (BH4) treatment. New therapeutic options will be analyzed.

Humans , Phenylalanine/adverse effects , Phenylketonurias/diagnosis , Phenylketonurias/therapy , Tyrosine/metabolism , Neurons/pathology , Phenylketonurias/physiopathology , Biopterin/analogs & derivatives , Early Diagnosis , Diet Therapy
Arch. argent. pediatr ; 117(4): 382-386, ago. 2019. ilus
Article in English, Spanish | LILACS, BINACIS | ID: biblio-1054941


La miopatía nemalínica es un trastorno heterogéneo definido por la presencia de estructuras con forma de bastones, conocidas como cuerpos nemalínicos (o bastones de nemalina). El diagnóstico se funda en la debilidad muscular, además de la visualización de cuerpos nemalínicos en la biopsia muscular. La miopatía nemalínica no tiene cura. Las estrategias terapéuticas para este trastorno son sintomáticas y empíricas. En este artículo, presentamos el caso de una recién nacida con insuficiencia respiratoria grave y debilidad muscular generalizada, a la que se le diagnosticó miopatía nemalínica a través de la biopsia muscular. La paciente tuvo una notable disminución de la sialorrea y una mejora de los movimientos espontáneos después del tratamiento con L-tirosina. Este caso se presenta para destacar la importancia de la biopsia muscular en el diagnóstico diferencial de la hipotonía grave durante el período neonatal y el posible beneficio del aporte suplementario de L-tirosina para disminuir la sialorrea y restaurar la fuerza muscular.

Nemaline myopathy (NM) is a heterogeneous disorder defined by the presence of rod-shaped structures known as nemaline bodies or rods. The diagnosis is based on muscle weakness, combined with visualization of nemaline bodies on muscle biopsy. There is no curative treatment for nemaline myopathy. Therapeutic strategies for this condition are symptomatic and empirical. Herein, we present a newborn with severe respiratory failure and generalized muscle weakness, who was diagnosed as NM by muscle biopsy. The patient experienced remarkable decrease in sialorrhea and improvement of spontaneous movements after L-tyrosine treatment. This case is presented to emphasize the importance of muscle biopsy in the differential diagnosis of severe hypotonia during neonatal period and a possible benefit of L-tyrosine supplementation for decreasing sialorrhea and restoring muscle strength.

Humans , Female , Infant, Newborn , Tyrosine/therapeutic use , Myopathies, Nemaline/diagnosis , Biopsy , Myopathies, Nemaline/therapy , Fatal Outcome , Muscle Hypotonia
Int. j. morphol ; 37(1): 65-70, 2019. graf
Article in English | LILACS | ID: biblio-990006


SUMMARY: Valproic acid (VPA), an antiepileptic drug, has been demonstrated to damage histology and to change tyrosine phosphorylation patterns with increased oxidative stress in perirenal tissues. This study aimed to investigate the effect of VPA on microstructure, tyrosine phosphorylation, and lipid peroxidation of rat kidney. Adult male rats were divided into control and VPA-treated groups intraperitoneally injected with normal saline and VPA 500 mg/kgBW for 10 consecutive days, respectively (n = 7 each). The blood serum was examined for biochemical levels. The kidney tissues were routinely processed for histological observation. Total proteins from kidney were extracted to assay the malondialdehyde (MDA) levels and phosphorylation expression. The results showed that VPA significantly decreased blood glucose levels while tend to increase urea nitrogen and creatinine. MDA levels in VPA group were significantly higher that of control. Renal cortex of VPA-treated animals revealed vasodilatations. Although the ratio of a renal phosphorylated 72 kDa protein/ beta actin expression seemed to be not different in both groups, VPA significantly decreased the intensity of beta actin. In conclusion, VPA dilates renal microvasculature with increasing of MDA but suppresses the actin expression.

RESUMEN: Se ha demostrado que el ácido valproico (AVP), un fármaco antiepiléptico, daña la histología y cambia los patrones de fosforilación de la tirosina con el aumento del estrés oxidativo en los tejidos perirrenales. Este estudio tuvo como objetivo investigar el efecto del AVP en la microestructura, la fosforilación de la tirosina y la peroxidación lipídica del riñón de rata. Se dividieron ratas macho adultas en grupos control y tratados con AVP. Durante 10 días consecutivos fueron inyectadas por vía intraperitoneal con solución salina normal y 500 mg / kg de PC respectivamente (n = 7 cada uno). Se analizó el suero sanguíneo para determinar los niveles bioquímicos. Los tejidos renales se procesaron de forma rutinaria para la observación histológica. Las proteínas totales del riñón se extrajeron para analizar los niveles de malondialdehído (MDA) y la expresión de la fosforilación. Los resultados mostraron que el AVP disminuyó significativamente los niveles de glucosa en la sangre, mientras que tienden a aumentar el nitrógeno ureico y la creatinina. Los niveles de MDA en el grupo de AVP fueron significativamente más altos que los del control. La corteza renal de los animales tratados con AVP reveló vasodilataciones. Aunque la proporción de una expresión de proteína / actina de 72 kDa fosforilada renal no parece ser diferente en ambos grupos, el AVP disminuyó significativamente la intensidad de la actina beta. En conclusión, el AVP dilata la microvasculatura renal al aumentar el MDA, pero suprime la expresión de actina.

Animals , Male , Rats , Tyrosine/drug effects , Lipid Peroxidation/drug effects , Valproic Acid/pharmacology , Kidney/drug effects , Anticonvulsants/pharmacology , Organ Size , Phosphorylation , Vasodilation/drug effects , Blotting, Western , Rats, Wistar , Electrophoresis, Polyacrylamide Gel , Malondialdehyde
Natural Product Sciences ; : 165-171, 2019.
Article in English | WPRIM | ID: wpr-760548


Although the functions of a standardized extract of Gingko biloba leaves (EGb 761®) has been reported with regard to neurobiological properties, no attention has been paid to the impact of EGb 761® on the neuronal regulation of energy homeostasis. To evaluate the hypothesis that EGb 761® affect the secretion of peptide tyrosine tyrosine (PYY) and the activation of free fatty acid receptor 4 (FFA4), which are involved in the neuronal circuitries that control energy homeostasis by inducing the transfer of information about the influx of energy to the brain, we examined whether EGb 761® can stimulate PYY secretion in the enteroendocrine NCI-H716 cells and if EGb 761® can activate FFA4 in FFA4-expressing cells. In NCI-H716 cells, EGb 761® stimulated PYY secretion and the EGb 761®-induced PYY secretion was involved in the increase in intracellular Ca2+ concentration and the activation of FFA4. Furthermore, in FFA4-expressing cells, EGb 761® activated FFA4. These results suggest that EGb 761® may affect the control of energy homeostasis via the regulation of PYY secretion and FFA4 activation.

Brain , Ginkgo biloba , Homeostasis , Neurons , Tyrosine
Chinese Journal of Biotechnology ; (12): 1247-1255, 2019.
Article in Chinese | WPRIM | ID: wpr-771804


L-tyrosine is one of three aromatic amino acids that are widely used in food, pharmaceutical and chemical industries. The transport system engineering provides an important research strategy for the metabolic engineering of Escherichia coli to breed L-tyrosine producing strain. The intracellular transport of L-tyrosine in E. coli is mainly regulated by two distinct permeases encoded by aroP and tyrP genes. The aroP and tyrP gene knockout mutants were constructed by CRISPR-Cas technique on the basis of L-tyrosine producing strain HGXP, and the effects of regulating transport system on L-tyrosine production were investigated by fermentation experiments. The fermentation results showed that the aroP and tyrP knockout mutants produced 3.74 and 3.45 g/L L-tyrosine, respectively, which were 19% and 10% higher than that of the original strain. The optimum induction temperature was determined to be 38 °C. Fed-batch fermentation was carried out on a 3-L fermentor. The L-tyrosine yields of aroP and tyrP knockout mutants were further increased to 44.5 and 35.1 g/L, respectively, which were 57% and 24% higher than that of the original strain. The research results are of great reference value for metabolic engineering of E. coli to produce L-tyrosine.

Escherichia coli , Escherichia coli Proteins , Gene Knockout Techniques , Metabolic Engineering , Tyrosine
Article in English | WPRIM | ID: wpr-763124


PURPOSE: The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). MATERIALS AND METHODS: We conducted a multi-center randomized phase II trial to compare the clinical outcomes between pemetrexed plus cisplatin combination therapy followed by maintenance pemetrexed (PC) and pemetrexed monotherapy (P) after failure of first-line EGFR-TKI. The primary objective was progression-free survival (PFS), and secondary objectives included overall response rate (ORR), overall survival (OS), health-related quality of life (HRQOL), and safety and toxicity profiles. RESULTS: A total of 96 patientswere randomized, and 91 patientswere treated at 14 centers in Korea. The ORR was 34.8% (16/46) for the PC arm and 17.8% (8/45) for the P arm (p=0.066). With 23.4 months of follow-up, the median PFS was 5.4 months in the PC arm and 6.4 months in the P arm (p=0.114). The median OS was 17.9 months and 15.7 months in PC and P arms, respectively (p=0.787). Adverse events ≥ grade 3 were reported in 12 patients (26.1%) in the PC arm and nine patients (20.0%) in the P arm (p=0.491). The overall time trends of HRQOL were not significantly different between the two arms. CONCLUSION: The outcomes of pemetrexed therapy in NSCLC patients with disease progression after firstline EGFR-TKI might not be improved by adding cisplatin.

Arm , Carcinoma, Non-Small-Cell Lung , Cisplatin , Disease Progression , Disease-Free Survival , Epidermal Growth Factor , Follow-Up Studies , Humans , Korea , Lung Neoplasms , Lung , Pemetrexed , Protein-Tyrosine Kinases , Quality of Life , ErbB Receptors , Tyrosine
Yonsei Medical Journal ; : 570-577, 2019.
Article in English | WPRIM | ID: wpr-762077


PURPOSE: Allergen-specific immunotherapy (AIT) is known to be the only therapeutic modality to alter the natural course of allergic diseases. However, at least 3 years of treatment is recommended for achieving long-term disease modifying effect. This study aimed to investigate factors associated with immunotherapy non-adherence in real practice. MATERIALS AND METHODS: We retrospectively reviewed medical records of patients who were diagnosed with allergic rhinitis, asthma, or atopic dermatitis, and received AIT to common allergens such as house dust mite and/or pollens from January 2007 to August 2014. In this study, non-adherence was defined as not completing 3 years of AIT. RESULTS: Among 1162 patients enrolled, 228 (19.6%) failed to complete 3 years of AIT. In multivariate analysis, age less than 20 years [odds ratio (OR) 3.11, 95% confidence interval (CI) 1.70–5.69] and 20 to 40 years (OR 2.01, 95% CI 1.17–3.43), cluster build-up (OR 1.78, 95% CI 1.05–3.02) and ultra-rush build-up schedules (OR 5.46, 95% CI 2.40–12.43), and absence of visit to other departments in the same hospital (OR 1.87, 95% CI 1.05–3.32) were independently associated with immunotherapy non-adherence. Disease duration of 5–10 years was negatively associated with non-adherence compared to shorter disease duration of less than 5 years (OR 0.61, 95% CI 0.40–0.94). Although male sex and commercial product of AIT, Tyrosine S®, compared to Novo-Helisen® were non-adherent factors in univariate analysis, no statistical significances were identified in multivariate analysis. CONCLUSION: Various factors are associated with immunotherapy adherence affecting the utility of immunotherapy. Clinicians should be aware of factors associated with adherence to maximize the utility of allergen-specific subcutaneous immunotherapy.

Allergens , Appointments and Schedules , Asthma , Dermatitis, Atopic , Humans , Immunotherapy , Male , Medical Records , Multivariate Analysis , Pollen , Pyroglyphidae , Retrospective Studies , Rhinitis, Allergic , Tyrosine
Article in English | WPRIM | ID: wpr-719707


PURPOSE: Despite the successful use of tyrosine kinase inhibitors (TKIs) in cancer patients, their effect on herpes zoster development has not been studied. The aim of this study was to evaluate and compare the effects of epidermal growth factor receptor (EGFR) TKI and cytotoxic chemotherapy on the risk of herpes zoster development in non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: We conducted a medical review of all eligible NSCLC patients in Seoul National University hospital between 2002 and 2015. We classified patients based on whether they previously underwent EGFR TKI therapy into either the TKI group or the cytotoxic group. We compared the incidence rates of herpes zoster during TKI therapy and cytotoxic chemotherapy. Additionally, the longitudinal risk of herpes zoster from TKIs was analyzed using the incidence rate ratio (IRR) of the TKI group to the cytotoxic group and the log-rank test of the Kaplan-Meier method. RESULTS: Of the 2,981 NSCLC patients, 54 patients (1.54%) developed herpes zoster. In the TKI group (2,002 patients), the IRR of herpes zoster during TKI therapy compared to that during cytotoxic chemotherapy was 1.05 (95% confidence interval [CI], 0.53 to 2.09). The IRR of the TKI group compared to the cytotoxic group was 1.33 (95% CI, 0.64 to 2.76). The Kaplan-Meier cumulative risk of both groups was not significantly different. CONCLUSION: Our results show that the incidence rate of herpes zoster in the TKI group was not statistically different from the incidence in the cytotoxic group during and after chemotherapy in NSCLC patients.

Carcinoma, Non-Small-Cell Lung , Drug Therapy , Erlotinib Hydrochloride , Herpes Zoster , Humans , Incidence , Methods , Protein-Tyrosine Kinases , ErbB Receptors , Seoul , Tyrosine
Article in English | WPRIM | ID: wpr-766105


PURPOSE: Several studies have shown that the oral cavity is a secondary location for Helicobacter pylori colonization and that H. pylori is associated with the severity of periodontitis. This study investigated whether H. pylori had an effect on the periodontium. We established an invasion model of a standard strain of H. pylori in human periodontal ligament fibroblasts (hPDLFs), and evaluated the effects of H. pylori on cell proliferation and cell cycle progression. METHODS: Different concentrations of H. pylori were used to infect hPDLFs, with 6 hours of co-culture. The multiplicity of infection in the low- and high-concentration groups was 10:1 and 100:1, respectively. The Cell Counting Kit-8 method and Ki-67 immunofluorescence were used to detect cell proliferation. Flow cytometry, quantitative real-time polymerase chain reaction, and western blots were used to detect cell cycle progression. In the high-concentration group, the invasion of H. pylori was observed by transmission electron microscopy. RESULTS: It was found that H. pylori invaded the fibroblasts, with cytoplasmic localization. Analyses of cell proliferation and flow cytometry showed that H. pylori inhibited the proliferation of periodontal fibroblasts by causing G2 phase arrest. The inhibition of proliferation and G2 phase arrest were more obvious in the high-concentration group. In the low-concentration group, the G2 phase regulatory factors cyclin dependent kinase 1 (CDK1) and cell division cycle 25C (Cdc25C) were upregulated, while cyclin B1 was inhibited. However, in the high-concentration group, cyclin B1 was upregulated and CDK1 was inhibited. Furthermore, the deactivated states of tyrosine phosphorylation of CDK1 (CDK1-Y15) and serine phosphorylation of Cdc25C (Cdc25C-S216) were upregulated after H. pylori infection. CONCLUSIONS: In our model, H. pylori inhibited the proliferation of hPDLFs and exerted an invasive effect, causing G2 phase arrest via the Cdc25C/CDK1/cyclin B1 signaling cascade. Its inhibitory effect on proliferation was stronger in the high-concentration group.

Blotting, Western , CDC2 Protein Kinase , Cell Count , Cell Cycle , Cell Proliferation , Coculture Techniques , Colon , Cyclin B1 , Cytoplasm , Fibroblasts , Flow Cytometry , Fluorescent Antibody Technique , G2 Phase , Helicobacter pylori , Helicobacter , Humans , Methods , Microscopy, Electron, Transmission , Mouth , Periodontal Ligament , Periodontitis , Periodontium , Phosphorylation , Real-Time Polymerase Chain Reaction , Serine , Tyrosine
Article in English | WPRIM | ID: wpr-764548


OBJECTIVES: Human epidermal growth factor receptor-2 (HER2) and 3 (HER3) belong to the epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases. In this study, we assessed HER2/HER3 expression levels in specimens of epithelial ovarian cancer and determined their correlation with clinical features of ovarian cancer. METHODS: Tissue microarrays (TMAs) were prepared from paraffin blocks of 105 ovarian tumour samples. HER2, HER3, PI3K, Akt, p-Akt, mTOR, p-mTOR, S6, and p-S6 expression levels were investigated using immunohistochemistry (IHC). HER2 and HER3 amplifications were determined using in situ hybridization (ISH). The correlation between HER2/3 expression and disease outcome of the patients including surgical outcome, progression-free survival (PFS) and overall survival (OS) was analysed. RESULTS: HER2 positivity was 3.8% by IHC and 5.7% by ISH, whereas that of HER3 was 12.4% and 8.6%, respectively. HER2 status by either IHC or ISH was not related to PFS (p=0.128, 0.168, respectively) and OS (p=0.245, 0.164, respectively). However, the HER3 status determined using fluorescence ISH was associated with poor PFS (p=0.035 on log rank test), which was a significant risk factor even after adjusting other possible risk factors in multivariate analysis (hazard ratio=2.377 [1.18–7.49], p=0.021). Expressions of Akt, p-mTOR, and S6 were also related with poor progression (p=0.008, 0.049, 0.014, respectively). CONCLUSION: HER3 is possibly an independent marker for poor prognosis in individuals with ovarian cancer, as the HER3 signalling pathway is distinct from that of HER2. The possibility of targeted therapy for patients with HER3 alteration in ovarian cancer should be evaluated.

Disease-Free Survival , Epidermal Growth Factor , Fluorescence , Humans , Immunohistochemistry , In Situ Hybridization , Multivariate Analysis , Ovarian Neoplasms , Paraffin , Phosphotransferases , Prognosis , ErbB Receptors , Risk Factors , Tyrosine
Journal of Breast Cancer ; : 362-374, 2019.
Article in English | WPRIM | ID: wpr-764284


PURPOSE: The chemical structure of tubulosine has been known since the mid-1960s. However, little is known about its biological and pharmacological functions. The aim of this study was to investigate the novel functions of tubulosine in cancer treatment, specifically in breast cancer. METHODS: An Unpaired (Upd)-induced Drosophila cell line and interleukin (IL)-6-stimulated human breast cancer cell lines were used to investigate the biological and pharmacological activities of tubulosine in vitro. To investigate the activities of tubulosine, we performed molecular and cellular experiments such as Western blot and reverse transcription polymerase chain reaction analyses, immunoprecipitation and terminal deoxynucleotidyl transferase dUTP nick end labeling assays, and immunofluorescence staining using breast cancer cell lines. RESULTS: Tubulosine exhibited anticancer activity in IL-6-stimulated human breast cancer cells. Moreover, tubulosine reduced the tyrosine phosphorylation level and transcriptional activity of signal transducer and activator of transcription (STAT) protein at 92E in Upd-induced Drosophila cells. Additionally, tubulosine suppressed IL-6-induced Janus kinase 2 (JAK2)/STAT3 signaling, resulting in decreased viability and induction of apoptotic cell death in breast cancer cells. Interestingly, inhibition of IL-6-induced JAK2/STAT3 signaling by tubulosine was associated with the blocking of IL-6 receptor (IL-6R) and glycoprotein 130 (gp130) binding. CONCLUSION: Tubulosine exhibits anticancer activity through functional inhibition of IL-6-induced JAK2/STAT3 signaling by targeting IL-6Rα/gp130 binding in breast cancer cells. These findings suggest that tubulosine may hold promise for the treatment of inflammation-associated cancers, including breast cancer.

Blotting, Western , Breast Neoplasms , Cell Death , Cell Line , DNA Nucleotidylexotransferase , Drosophila , Fluorescent Antibody Technique , Glycoproteins , Humans , Immunoprecipitation , In Vitro Techniques , Interleukin-6 , Interleukins , Janus Kinase 2 , Phosphorylation , Phosphotransferases , Polymerase Chain Reaction , Receptors, Interleukin-6 , Reverse Transcription , STAT3 Transcription Factor , Transducers , Tyrosine